Thu Sep 19 07:22:44 UTC 2024: ## Elevance Health (ELV) Receives “Buy” Rating from Analysts, Shares Up

**New York, NY** – Shares of Elevance Health, Inc. (NYSE: ELV) are currently enjoying a “Buy” consensus rating from analysts, according to Marketbeat. Out of the fifteen firms covering the company, thirteen have issued a “Buy” recommendation, one a “Strong Buy,” and only one a “Hold.” This positive sentiment is further reflected in the average twelve-month price target of $604.29 set by analysts.

Recent analyst activity has seen price targets adjusted, including increases from JPMorgan Chase & Co. and Truist Financial, who both maintain their “Overweight” and “Buy” ratings, respectively. Wells Fargo & Company lowered their price target but still holds an “Overweight” rating. Notably, Baird R W upgraded Elevance Health to a “Strong Buy” rating.

Elevance Health’s Q2 earnings report, released on July 17th, showcased strong performance. The company exceeded earnings per share expectations by $0.13, reporting $10.12 EPS, and revenue also surpassed estimates at $43.22 billion. While revenue dipped slightly compared to the same quarter last year, analysts project a robust 37.25 EPS for the current fiscal year.

The company also announced a quarterly dividend of $1.63 per share, representing a $6.52 annualized dividend and a yield of 1.21%.

Insider trading activity saw CEO Gail Boudreaux selling 34,000 shares in July, while Director Ramiro G. Peru sold 753 shares in August. Institutional investors own a significant 89.24% of Elevance Health’s stock.

Elevance Health, Inc., operates as a health benefits company in the United States, offering a wide range of health plans and services. The company’s strong financial performance and positive analyst outlook make it a promising investment opportunity in the healthcare sector.

Read More